Helicobacter pylori Vaccines
Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against disease caused by Helicobacter pylori and guarantee the finest results for our customers all over the world.
Helicobacter pylori (H. pylori) is a Gram-negative, microaerophilic bacterium that grows in the digestive tract and tends to attack the stomach lining. It is a common contagious cause of ulcers worldwide. It is a ubiquitous organism and infects the stomachs of roughly 60% of the world’s adult population. H. pylori infections are usually harmless, it can cause atrophic and even metaplastic changes in the stomach, and it has a known association with peptic ulcer disease. The infection will never have any signs or symptoms in most people and the most common route of H. pylori infection is either oral-to-oral or fecal-to-oral contact.
H. pylori Urease B Subunit Vaccines
The H. pylori urease B subunit vaccine utilized an efficient nanoparticle system for vaccination to achieve both cargo protection and mucosal penetration. This delivery system is comprised of an anionic, hydrophilic, mercaptosuccinic acid-functionalized poly (ethylene glycol) derivative and the transepithelial penetration was achieved by the cell-penetrating peptide poly-L-arginine. Mixed with the recombination urease subunit B, which is a candidate vaccine against H. pylori, both components were subjected to a mild electrostatic self-assembly process to obtain nanoparticles. This vaccine could significantly enhance systemic and mucosal antibody levels in mice, and these immune responses protect the animals from H. pylori challenge. These results suggest that the PEGylated nanoparticles can be a powerful platform for building an oral vaccine to protect against gastrointestinal infection by recalcitrant H. pylori.
VacA-Based Vaccine
Vacuolating cytotoxin (VacA) causes acute gastric epithelial erosion and ulceration, which excludes the use of the active toxin in humans. When the vaccination by intragastrically in mice with the non-toxic recombinant VacA combined with the non-toxic mutant of E. coli heat-labile enterotoxin (LT), it is not only successfully eradicates H. pylori infection but also prevents a subsequent reinfection. In addition, immunization with the whole VacA molecule which is fused with a fragment of VacA (aa 744-805) that contains CD4+ T cell epitopes to cytotoxin-associated gene A (CagA) and urease B fragments and expressed the fusion protein into an attenuated Salmonella vector, was able to elicit significant protection against experimental H. pylori challenge. Oral therapeutic immunization with this attenuated Salmonella expressing the CagA-VacA-UreB fusion protein, significantly decreased H. pylori colonization.
DNA Vaccine
There is a live attenuated S. typhi strain harboring the H. pylori NAP. When administered orally to mice, this vaccine was able to generate both humoral and mucosal immune responses. Besides, another recombinant S. typhi DNA vaccine expressing urease-B protein and interleukin 2 protein showed good immunogenic response in an animal model. They could become feasible for treating H. pylori infection in the future.
Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against disease caused by Helicobacter pylori. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
